This 2018 review examines the potential of alpha-lipoic acid (ALA) and acetyl-L-carnitine (ALC) in managing chemotherapy-induced peripheral neuropathy (CIPN). ALA's antioxidant and anti-inflammatory properties have shown promise in preclinical studies, but clinical trials yield mixed results, with efficacy influenced by administration routes. ALC demonstrates benefits in vitro and in animal
